Creo Medical Announces First Patient Treated with Speedboat

Progression of first commercial product on track

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, is pleased to announce the first clinical use of the Company’s Speedboat device.

The first patient with a large pre-cancerous lesion in the gastrointestinal (GI) tract was treated using Creo’s Speedboat device powered by Creo’s CROMA electrosurgery advanced energy platform. The patient was treated by Professor Brian Saunders at St. Mark’s Hospital in London, United Kingdom.

Craig Gulliford, Chief Executive Officer of Creo Medical, commented:

The first treatment of a patient is a significant inflection in the commercialisation of our first product from the endoscopic pipeline. In-line with our strategy, we are increasing surgeon training to expand clinical awareness and bring the benefits of this important new development to those patients in need. We have a complementary range of products in development and believe that this positions Creo well to become a leader in this growing billion dollar market. We look forward to treating more patients in the near future and sharing our experience with the wider clinical community.

The Speedboat device harnesses the precise cut and coagulation capability of CROMA to remove early cancerous and pre-cancerous lesions in the bowel. The use of the Speedboat device helps reduce the risks associated with alternative laparoscopic procedures, reducing the length of hospital stays and transferring therapy from the operating room to the endoscopy room

Endoscopy has been a rapidly expanding practice due to the advent of colorectal cancer screening in most healthcare systems. This has driven growth in equipment and devices to enhance the ability to screen, detect and treat early stage and pre-cancerous lesions in the GI tract.

Posted 06/17/17

For press enquiries please contact For all other enquiries please visit our Contact page.

Further news

19 March 2024

Welsh Labour Leader visits Creo’s facilities


05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi


31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific


10 January 2024

First Use of Speedboat® UltraSlim in Latin America


13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch


01 November 2023

Speedboat® UltraSlim: US FDA Clearance


25 October 2023

Speedboat UltraSlim: EU launch accelerated by 18 months


12 September 2023

Half Year Report: H1-2023


19 June 2023

Speedboat Inject cleared for upper GI use in Europe


01 June 2023

Speedboat™ Inject selected by NICE for assessment